UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2024
Commission File Number 001-41923
EUPRAXIA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)
N/A
(Translation of Registrant’s name)
201-2067 Cadboro Bay Road
Victoria, British Columbia, Canada V8R 5G4
Telephone: (250) 590-3968
(Address and telephone number of registrant’s
principal executive offices)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☐ Form
40-F ☒
DOCUMENTS INCLUDED AS PART OF THIS REPORT
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Eupraxia Pharmaceuticals Inc.
|
Date: July 8,
2024 |
|
|
|
By: |
|
/s/ Bruce Cousins |
|
|
|
|
|
|
Name: Bruce Cousins |
|
|
|
|
|
|
Title: President and Chief Financial Officer |
Exhibit 99.1
![](https://www.sec.gov/Archives/edgar/data/1581178/000127956924000857/logo.jpg)
Eupraxia Pharmaceuticals to Present
at Controlled Release Society 2024
Annual Meeting and Expo
Victoria, B.C. - July 8, 2024
- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology
company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need,
today announced that the Company’s Chief Operating and Scientific Officer, Dr. Amanda Malone, will be presenting at the upcoming
Controlled Release Society 2024 Annual Meeting and Expo being held in Bologna, Italy from July 8-12, 2024.
Presentation Details:
Abstract ID: |
4085079 |
Presentation Title: |
EP-104, a novel microparticle formulation achieving extended-release of fluticasone propionate |
Session Type: |
Oral Abstract Presentation |
Session Title: |
Long-Acting Drug Delivery Formulations - Session #2 |
Session Date & Time: |
July 10, 2024, from 9:00 AM to 11:00 AM CEST (3:00 AM to 5:00 AM ET) |
The presentation will also be available on Eupraxia's website at:
https://eupraxiapharma.com/our-science/clinical-trials-and-publications/default.aspx.
About Eupraxia Pharmaceuticals Inc.
Eupraxia is a clinical-stage biotechnology
company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas
with high unmet medical need. The Company strives to provide improved patient benefit and has developed technology designed to deliver
targeted, long-lasting activity with fewer side effects. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is
designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tuneable pharmacokinetic
(PK) profiles. This investigational technology can be engineered for use with multiple active pharmaceutical ingredients and delivery
methods.
Eupraxia’s EP-104GI is currently
in a Phase 1b/2a trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (“EoE”). EP-104GI is administered
as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also
recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to osteoarthritis of the knee.
The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later
and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications
and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia,
please visit the Company's website at: www.eupraxiapharma.com.
1
Notice Regarding Forward-looking Statements
and Information
This news release includes forward-looking
statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information
can be identified by the use of words such as "plans", "is expected", "expects", “suggests”,
"scheduled", "intends", "contemplates", "anticipates", "believes", "proposes",
"potential" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions,
events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved.
Forward looking statements in this news release include statements regarding the details of the Company’s presentation at the upcoming
Controlled Release Society 2024 Annual Meeting and Expo; the Company's product candidates, including expected benefits to patients with
respect to safety, efficacy, duration and tolerability; the results gathered from studies and trials of Eupraxia's product candidates;
the potential for the Company's technology to impact the drug delivery process; potential market opportunity for the Company’s products,
and potential pipeline indications. Such statements and information are based on the current expectations of Eupraxia's management, and
are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially
as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability
to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability
to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and
information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release
may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting
Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel
technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product
candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current
license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for
its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to
obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's
clinical trials may fail to demonstrate adequately the safety and efficacy of our product candidates at any stage of clinical development;
the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely
relies on third parties to provide supplies and inputs required for its products and services; the Company relies on external contract
research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its
business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will
be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory
approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement
of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence
and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public
filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted to identify important factors that could cause actual
actions, events or results to differ materially from those described in forward-looking statements and information, there may be other
factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or
information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only
as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement
or information, whether as a result of new information, future events or otherwise.
For investor and media inquiries, please contact:
Danielle Egan, Eupraxia Pharmaceuticals Inc.
778.401.3302
degan@eupraxiapharma.com
or
Adam Peeler, on behalf of:
Eupraxia Pharmaceuticals Inc.
416.427.1235
adam.peeler@loderockadvisors.com
SOURCE Eupraxia Pharmaceuticals Inc.
Grafico Azioni Eupraxia Pharmaceuticals (NASDAQ:EPRX)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Eupraxia Pharmaceuticals (NASDAQ:EPRX)
Storico
Da Set 2023 a Set 2024